For this reason, a second therapy was added which was based on intraprostatic injection of tumor cells expressing an antigen called LIGHT, which is able to recruit and activate T cells to the tumor site, causing rejection of antigenically unrelated tumors. This evidence concerns the gene TNFSF14 and neoplasm.